PRESS RELEASES

Date Title View
Toggle Summary Chimerix Presents Results from Post-hoc Analysis of Phase 3 Study
Decreased HHV-6 Reactivation Observed Among Oral Brincidofovir Allogeneic Hematopoietic Cell Transplantation Recipients Results to be Presented at Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR 2019 DURHAM, N.C. , Feb. 22, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a
View HTML
Toggle Summary Chimerix Announces Management Transition
M. Michelle Berrey to Step Down as Chief Executive Officer DURHAM, N.C. , Feb. 06, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that M.
View HTML
Toggle Summary Chimerix to Present at the 37th Annual J.P. Morgan Healthcare Conference
DURHAM, N.C. , Jan. 04, 2019 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that M. Michelle Berrey , M.D., M.P.H, President and Chief Executive Officer of Chimerix, will present at
View HTML
Toggle Summary Chimerix Announces Third Quarter 2018 Financial Results
- Conference Call at 8:30 a.m. ET Today - DURHAM, N.C. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today reported financial results and provided a corporate update for the third
View HTML
Toggle Summary Chimerix to Present at the Stifel 2018 Healthcare Conference
DURHAM, N.C. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that M. Michelle Berrey , M.D., M.P.H., Chief Executive Officer and Tim Trost, Chief Financial
View HTML
Toggle Summary Chimerix to Announce Third Quarter 2018 Financial Results on November 8, 2018
DURHAM, N.C. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that it will host a live conference call and audio webcast on Thursday, November 8, 2018 at 8:30 a.m.
View HTML
Toggle Summary Chimerix Presents Preclinical Data Demonstrating Antiviral Activity of Brincidofovir Against Polyomavirus at Kidney Week 2018
Data supports further clinical evaluation of brincidofovir for the treatment and prevention of BK virus DURHAM, N.C. , Oct. 27, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced data from two preclinical studies which assessed the in vivo antiviral activity of brincidofovir (BCV)
View HTML
Toggle Summary Chimerix to Host Annual Investor Update on October 17, 2018
DURHAM, N.C. , Oct. 11, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that it will host the Company's annual investor update on October 17, 2018, at 4:30 p.m. ET in New York .
View HTML
Toggle Summary Chimerix Presents Results from Multiple Ascending Dose Study of IV Brincidofovir at IDWeek
DURHAM, N.C. , Oct. 05, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced data from the company’s Phase 1 study evaluating the safety and pharmacokinetics (PK) of multiple ascending doses (MAD) of
View HTML
Toggle Summary Landmark AdVance Study Shows Adenovirus Burden Correlates with Mortality in Pediatric Allogeneic Hematopoietic Cell Transplant Recipients
– First Study to Show that Adenovirus Area Under the Curve is an Optimal Indicator of Clinical Outcomes in Adenovirus Infection – DURHAM, N.C. , Oct. 04, 2018 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today
View HTML